DEK promotes HPV-positive and -negative Head and neck cancer cell proliferation

Oncogene

Volumn 34, Issue 7, 2015, Pages 868-877

  Adams, A K ^a   Hallenbeck, G E ^a   Casper, K A ^b   Patil, Y J ^b   Wilson, K M ^b   Kimple, R J ^c   Lambert, P F ^c   Witte, D P ^a   Xiao, W ^d   Gillison, M L ^d   Wikenheiser Brokamp, K A ^e   Wise Draper, T M ^a,f   Wells, S I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEK PROTEIN; PEPTIDES AND PROTEINS; PROTEIN P53; UNCLASSIFIED DRUG; DEK PROTEIN, HUMAN; DEK PROTEIN, MOUSE; DNA BINDING PROTEIN; NONHISTONE PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PHOSPHOPROTEIN; PROTEIN E7; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRP63 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS CELL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; MEDICAL RECORD REVIEW; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; GENETICS; HEAD AND NECK TUMOR; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

HUMAN PAPILLOMAVIRUS; MUS; MUS MUSCULUS; NICOTIANA TABACUM;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PHOSPHOPROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84938496126     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.15     Document Type: Article

References (42)

1. Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ et al. Head and neck cancers. J Natl Compr Canc Netw 2008;6:646-695.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L et al. Evidence for a causal association between human papillomavirusand a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
4. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl J Med 2010;363:24-35.
5. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013;73:4791-4800.
6. Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer 2009;125:2159-2165.
7. Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI. Future directions and treatment strategies for head and neck squamous cell carcinomas. Transl Res 2012;160:167-177.
8. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992;12:1687-1697.
9. Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 2000;14:1308-1312.
10. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005;79:14309-14317.
11. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006;26:7506-7519.
12. Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 2009;174:71-81.
13. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA et al. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009;69:1792-1799.
14. Jabbar S, Strati K, Shin MK, Pitot HC, Lambert PF. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology 2010;407:60-67.
15. Strati K, Lambert PF. Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res 2007;67:11585-11593.
16. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirustype 16 E7 oncogene. J Virol 1996;70:1873-1881.
17. Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009;69:6405-6413.
18. Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene 2011;30:2741-2752.
19. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006;5:1202-1207.
20. Lu ZL, Luo DZ, Wen JM. Expression and significance of tumor-related genes in HCC. World J Gastroenterol 2005;11:3850-3854.
21. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-661.
22. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-5183.
23. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004;2:371-386.
24. Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer 2013;13:136-143.
25. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
26. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
27. Liu S, Wang X, Sun F, Kong J, Li Z, Lin Z. DEK overexpression is correlated with the clinical features of breast cancer. Pathol Int 2012;62:176-181.
28. Privette Vinnedge LM, Ho SM, Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLoS One 2012;7:e46985.
29. Sitwala KV, Adams K, Markovitz DM. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene 2002;21:8862-8870.
30. Alexandrova EM, Petrenko O, Nemajerova A, Romano RA, Sinha S, Moll UM. DeltaNp63 regulates select routes of reprogramming via multiple mechanisms. Cell Death Differ 2013;20:1698-1708.
31. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev 2006;20:3185-3197.
32. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, Karin M et al. p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci USA 2007;104:3255-3260.
33. Pignon JC, Grisanzio C, Geng Y, Song J, Shivdasani RA, Signoretti S. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci USA 2013;110:8105-8110.
34. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713.
35. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718.
36. Romano RA, Smalley K, Magraw C, Serna VA, Kurita T, Raghavan S et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 2012;139:772-782.
37. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-1160.
38. Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N et al. DEK is a poly (ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 2008;28:3245-3257.
39. Hoskins EE, Morris TA, Higginbotham JM, Spardy N, Cha E, Kelly P et al. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 2009;28:674-685.
40. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-4301.
41. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9:45-56.
42. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 2006;103:14152-14157.